TPO and neutropenia: Additionally, TPO-RAs reduced the occurrence of neutropenia (OR = 0.49; 95% CI: 0.32–0.75) (I2 = 0.0%, p = 0.659) and anemia (OR = 0.59; 95% CI: 0.38–0.91) (I2 = 0.0%, p = 0.824) (Figure 3B).